Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Case Report

Drug-aggravated Bullous Pemphigoid in a 47-year-old Asian Woman - A Case Report

Author(s): Divyajayashree Nelramachandrakumar, Haritha Hariharan, Senthilvel Nagamanickam and Sam Johnson Udaya Chander J.*

Volume 18, Issue 3, 2023

Published on: 11 August, 2022

Page: [379 - 382] Pages: 4

DOI: 10.2174/1574886317666220518091554

Price: $65

conference banner
Abstract

Introduction: Bullous pemphigoid is the most common chronic recurrent autoimmune subepidermal blistering disorder most prevalent in the geriatric population. It varies widely in clinical presentation ranging from tense bullae to intense generalized pruritus. It is immunologic in origin with the presence of IgG antibodies.

Case Report: A 47-year-old female presented to the hospital with complaints of blisters in the lower limbs, which she self managed with neem oil, after which the blisters occurred over the body. The patient also experienced blisters over both upper and lower limbs, gluteal region, painful generalized ulcers, necrotic patches, multiple erythematous blisters, ulcer erosions over bilateral legs and upper limbs with few lesions, which were foul-smelling and oozing. On the second day of admission, the patient’s CRP and ESR levels were tested and the levels were 33.5 and 35 mm/hr, respectively. The patient was treated with an injection of meropenem 1 g three times daily, dexamethasone 4 mg once daily, and ofloxacin 400 mg once daily. On the third day of admission, the patient complained of leg swelling, and subsequently, D-Dimer levels were checked, which showed a value of 5,740 and was treated with an injection of enoxaparin 40 mg for the same throughout the course of the hospital stay A skin biopsy confirmed the diagnosis of bullous pemphigoid. The culture test showed the growth of Klebsiella pneumonia and Acinetobacter baumani, which were resistant to most of the antibiotics. The patient was managed appropriately with modalities including antibiotics, anti-inflammatory agents, immunosuppressants, multivitamins, fluids, and albumin. The patient responded well to the treatment without new lesions or fever spikes. There was the presence of necrotic patches of old lesions alone at the time of discharge.

Conclusion: This case report was done with the purpose of presenting an exemplary case of bullous pemphigoid aggravated by the application of neem oil and emphasizing the inappropriate use of folk medicine in an autoimmune disease like bullous pemphigoid.

Keywords: Autoimmune disease, bullous pemphigoid, folk medicine, erythematous blister, exaggeration, sepsis.

[1]
Miyamoto D, Santi CG, Aoki V, Maruta CW. Bullous pemphigoid. An Bras Dermatol 2019; 94(2): 133-46.
[http://dx.doi.org/10.1590/abd1806-4841.20199007] [PMID: 31090818]
[2]
Chowdhury J, Datta PK, Chowdhury SN, Das NK. A clinicopathological study of pemphigus in Eastern India with special reference to direct immunofluorescence. Indian J Dermatol 2016; 61(3): 288-94.
[http://dx.doi.org/10.4103/0019-5154.182422] [PMID: 27293249]
[3]
Joly P, Roujeau J-C, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346(5): 321-7.
[http://dx.doi.org/10.1056/NEJMoa011592] [PMID: 11821508]
[4]
Khaddour HH, Zaher D, Kassem T, Hasan A. Aggressive refractory Pemphigus vulgaris that responded to plasmapheresis: A case report. J Med Case Reports 2020; 14(1): 109.
[http://dx.doi.org/10.1186/s13256-020-02421-w] [PMID: 32682443]
[5]
Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: A review of the literature. J Eur Acad Dermatol Venereol 2014; 28(9): 1133-40.
[http://dx.doi.org/10.1111/jdv.12366] [PMID: 24404939]
[6]
Baigrie D, Nookala V. Bullous Pemphigoid StatPearls. 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535374/
[7]
Kridin K, Ludwig RJ. The growing incidence of bullous pemphigoid: Overview and potential explanations. Front Med (Lausanne) 2018; 5: 220.
[http://dx.doi.org/10.3389/fmed.2018.00220] [PMID: 30177969]
[8]
Spivey J, Nye AM. Bullous pemphigoid: Corticosteroid treatment and adverse effects in long-term care patients. Consult Pharm 2013; 28(7): 455-62.
[http://dx.doi.org/10.4140/TCP.n.2013.455] [PMID: 23835463]
[9]
Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: The european dermatology forum consensus in collaboration with the european academy of dermatology and venereology. Br J Dermatol 2015; 172(4): 867-77.
[http://dx.doi.org/10.1111/bjd.13717] [PMID: 25827742]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy